New hope for transplant patients: drug combo may tame deadly immune attack
Disease control
Recruiting now
This study tests a drug called ruxolitinib for treating acute graft-versus-host disease (GVHD), a serious condition where donor cells attack the patient's body after a bone marrow transplant. About 98 adults with moderate to severe GVHD will receive either ruxolitinib alone or wi…
Phase: PHASE2 • Sponsor: John Levine • Aim: Disease control
Last updated May 08, 2026 12:03 UTC